LEISCHNER FIALOVÁ, Jindřiška, Martina RAUDENSKÁ, Milan JAKUBEK, Zdenek KEJIK, Pavel MARTÁSEK, Petr BABULA, Adam MATKOWSKI, Petr FILIPENSKY and Michal MASAŘÍK. Novel Mitochondria-targeted Drugs for Cancer Therapy. Mini-reviews in medicinal chemistry. SHARJAH: BENTHAM SCIENCE PUBL LTD, 2021, vol. 21, No 7, p. 816-832. ISSN 1389-5575. Available from: https://dx.doi.org/10.2174/1389557520666201118153242.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Novel Mitochondria-targeted Drugs for Cancer Therapy
Authors LEISCHNER FIALOVÁ, Jindřiška (203 Czech Republic, guarantor, belonging to the institution), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Milan JAKUBEK (203 Czech Republic), Zdenek KEJIK (203 Czech Republic), Pavel MARTÁSEK (203 Czech Republic), Petr BABULA (203 Czech Republic, belonging to the institution), Adam MATKOWSKI (616 Poland), Petr FILIPENSKY (203 Czech Republic) and Michal MASAŘÍK (203 Czech Republic, belonging to the institution).
Edition Mini-reviews in medicinal chemistry, SHARJAH, BENTHAM SCIENCE PUBL LTD, 2021, 1389-5575.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30107 Medicinal chemistry
Country of publisher United Arab Emirates
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.737
RIV identification code RIV/00216224:14110/21:00118840
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.2174/1389557520666201118153242
UT WoS 000631285400003
Keywords in English Mitochondria; targeting; metabolism; cancer; treatment; inhibitors; hexokinase; tricarboxylic acid cycle; respiratory chain; electron transport chain
Tags 14110515, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 23/8/2021 14:13.
Abstract
The search for mitochondria-targeted drugs has dramatically risen over the last decade. Mitochondria are essential organelles serving not only as a powerhouse of the cell but also as a key player in cell proliferation and cell death. Their central role in the energetic metabolism, calcium homeostasis and apoptosis makes them an intriguing field of interest for cancer pharmacology. In cancer cells, many mitochondrial signaling and metabolic pathways are altered. These changes contribute to cancer development and progression. Due to changes in mitochondrial metabolism and changes in membrane potential, cancer cells are more susceptible to mitochondria-targeted therapy. The loss of functional mitochondria leads to the arrest of cancer progression and/or a cancer cell death. Identification of mitochondrial changes specific for tumor growth and progression, rational development of new mitochondria-targeted drugs and research on delivery agents led to the advance of this promising area. This review will highlight the current findings in mitochondrial biology, which are important for cancer initiation, progression and resistance, and discuss approaches of cancer pharmacology with a special focus on the anti-cancer drugs referred to as ‘mitocans’.
Links
GA18-03978S, research and development projectName: Efekt buněčné tuhosti a mikroprostředí jako prediktor odpovědi na léčbu karcinomů hlavy a krku
Investor: Czech Science Foundation
LM2018133, research and development projectName: Český národní uzel Evropské infrastruktury pro translační medicínu (Acronym: EATRIS-ERIC-CZ)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1307/2019, interní kód MUName: Kardiovaskulární systém od A do Z (Acronym: KAVASAZ)
Investor: Masaryk University, Category A
MUNI/A/1453/2019, interní kód MUName: Příspěvek ke studiu molekulární, buněčné, tkáňové a systémové patofyziologie vybraných komplexních nemocí
Investor: Masaryk University, Category A
NV18-08-00229, research and development projectName: Interakce buněk nádorového mikroprostředí jako nový nástroj predikce účinnosti terapie nádorů hlavy a krku
Investor: Ministry of Health of the CR
PrintDisplayed: 8/6/2024 23:13